KCNH1 Antibody

What is KCNH1 and why is it important in research?

KCNH1 is a voltage-gated potassium channel that contains tetrameric α subunits, each consisting of 6 membrane-spanning α-helices (S1-S6). The S1-S4 segments function as voltage sensor domains, while S5 and S6 form the pore-lining loop . Originally identified in Drosophila melanogaster where its mutation caused a rhythmic leg-shaking phenotype under ether anesthesia (hence the name "ether à go-go"), KCNH1 has emerged as critical in two research areas:

• Neurodevelopmental disorders: Variants in KCNH1 are associated with Temple-Baraitser syndrome (TBS) and Zimmermann-Laband syndrome (ZLS), characterized by intellectual disability, developmental disorders, digital/toe anomalies, and epilepsy .

• Oncology: KCNH1 shows aberrant expression in various cancers, with research indicating its potential as a cancer biomarker and therapeutic target .

What applications are KCNH1 antibodies validated for?

Based on the literature and commercial antibody validation data, KCNH1 antibodies have been successfully employed in:

KCNH1 antibodies have been successfully applied in studies examining brain tissue, cervical cytologies, cancer cell lines, and heterologous expression systems .

What positive controls should be used to validate KCNH1 antibodies?

When validating KCNH1 antibodies, the following positive controls are recommended:

• Tissue samples: Human or rat brain tissue (particularly hippocampus)

• Cell lines: HEK293T cells transfected with KCNH1

• Cancer cell lines: MDA-468 mammary gland adenocarcinoma cells , HeLa cells

• Recombinant protein: Purified KCNH1 protein for antibody specificity testing

For negative controls, comparing staining patterns with pre-immune serum, using KCNH1 blocking peptides, or utilizing tissue from KCNH1 knockout models is recommended .

How can I distinguish between KCNH1 and related potassium channels?

KCNH1 belongs to the ether-à-go-go family that includes eight members: KCNH1 (KV10.1), KCNH2 (KV10.2), and the KV11 (erg) and KV12 (elk) subfamilies .

When selecting antibodies:

• Choose antibodies raised against unique regions (particularly the C-terminus) that have minimal sequence homology with related channels

• Perform Western blot analysis on tissues expressing multiple family members to confirm specificity

• Include appropriate positive controls such as HEK cells transfected with KCNH1

• Test with blocking peptides to confirm specificity

For example, the antibody described in source was designed to recognize KV10.1 from rat, human, and mouse samples and has been verified not to cross-react with KV10.2.

What are the optimal fixation and sample preparation protocols for KCNH1 immunohistochemistry?

For optimal KCNH1 detection in different tissue types:

Paraffin-embedded tissue sections:

• Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is critical for exposing KCNH1 epitopes

• Block with 10% normal goat serum to reduce non-specific binding

• Incubate with primary antibody (1:50-1:200 dilution) overnight at 4°C

• Use biotin-streptavidin detection systems with DAB as chromogen for enhanced sensitivity

Immunofluorescence in cultured cells:

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.1% Triton X-100 for 10 minutes

• Block with 10% normal goat serum

• Incubate with anti-KCNH1 antibody (2 μg/mL) overnight at 4°C

• Use appropriate fluorophore-conjugated secondary antibodies (e.g., DyLight®488)

• Counterstain nuclei with DAPI

How can I optimize Western blot protocols for detecting KCNH1?

KCNH1 is a large transmembrane protein that requires specific conditions for optimal detection:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors for tissue lysis

  • Avoid boiling samples (heat to 70°C for 10 minutes) to prevent aggregation

  • Include 5mM EDTA and 1mM DTT in lysis buffer

• Gel electrophoresis:

  • Use 5-8% polyacrylamide gels due to KCNH1's high molecular weight

  • Load 30-50 μg protein per lane

  • Run at lower voltage (70-90V) for better resolution

• Transfer conditions:

  • Transfer at 150 mA for 50-90 minutes to ensure complete transfer

  • Use nitrocellulose membranes for optimal binding

• Detection optimization:

  • Block with 5% non-fat milk in TBS

  • Use antibody concentrations of 0.5-1.0 μg/mL

  • Incubate primary antibody overnight at 4°C

  • Use enhanced chemiluminescence (ECL) detection systems

How can KCNH1 antibodies be used to study neurodevelopmental disorders?

KCNH1 variants cause a spectrum of epileptic disorders ranging from benign forms of genetic isolated epilepsy/febrile seizure to intractable epileptic encephalopathy . Researchers can use KCNH1 antibodies to:

• Characterize variant-specific expression patterns:

  • Compare KCNH1 protein localization in patient-derived cells versus controls

  • Evaluate the impact of variants on protein expression levels

  • Assess subcellular localization changes in neurons

• Investigate genotype-phenotype correlations:

  • Analyze KCNH1 expression in relation to variant location (e.g., transmembrane domains vs. intracellular regions)

  • Compare expression patterns between de novo variants (associated with epileptic encephalopathy) and inherited/mosaic variants (associated with isolated epilepsy)

• Study region-specific expression:

  • Map KCNH1 expression across brain regions in animal models

  • Correlate expression patterns with epilepsy phenotypes

Research has shown that KCNH1 variants located in specific regions correlate with distinct clinical presentations - variants in transmembrane domains (S4 and S6) cluster with epileptic encephalopathy, while variants in other regions associate with isolated epilepsy/seizures or syndromes without epilepsy .

What are the experimental challenges in studying KCNH1 variants?

Investigating KCNH1 variants presents several technical challenges:

• Variant-specific antibody limitations:

  • Standard antibodies cannot distinguish between wild-type and variant KCNH1

  • Researchers must rely on heterologous expression systems and co-localization studies

• Functional correlation:

  • Connecting antibody-based expression studies with electrophysiological data requires combined approaches

  • Consider using patch-clamp electrophysiology in conjunction with immunostaining

• Model systems:

  • Patient-derived cells may not recapitulate neural network complexity

  • Animal models may not fully reproduce human phenotypes

  • Consider using human iPSC-derived neurons for more physiologically relevant studies

Recent research used HEK293T cells to heterologously express wild-type or variant KCNH1, finding that disease-associated variants exhibit gain-of-function properties with significant effects on resting membrane potential .

How can KCNH1 antibodies be utilized in cancer research?

KCNH1 has been implicated in malignant tumor development and is aberrantly expressed in several cancer cell lines . KCNH1 antibodies can be employed in cancer research in the following ways:

• Cancer diagnostics and biomarker development:

  • Evaluate KCNH1 expression in tumor biopsies

  • Develop immunohistochemical scoring systems correlating expression with prognosis

  • Analyze cervical cytologies for KCNH1 expression, which shows association with pregnancy and HPV infection

• Therapeutic target validation:

  • Screen cancer cells for KCNH1 expression before testing channel blockers

  • Monitor changes in KCNH1 expression following treatment

  • Assess the efficacy of CAR-T cell approaches targeting KCNH1 in brainstem glioma

• Prognostic studies:

  • Compare KCNH1 expression between normal and cancer tissues

  • Correlate expression levels with clinical outcomes

  • Investigate association with other cancer biomarkers

Research has demonstrated KCNH1 expression in 100% of cervical cytologies from pregnant patients compared to only 26.6% in non-pregnant controls, suggesting hormonal regulation . This observation points to potential applications in reproductive biology research.

What considerations should be made when using KCNH1 antibodies in cancer tissue analysis?

When employing KCNH1 antibodies for cancer tissue analysis:

• Tissue heterogeneity:

  • Include multiple regions from the same tumor to account for expression heterogeneity

  • Use careful microdissection techniques to separate tumor from stroma

• Quantification approaches:

  • Implement digital image analysis for objective quantification

  • Measure signal intensity as pixels per cell nuclei area

  • Use standardized scoring systems for consistency across studies

• Confounding factors:

  • Control for HPV status in cervical samples, as research shows no correlation between percentage of KCNH1-positive cells and HPV type

  • Consider hormonal influences, as progesterone induces KCNH1 expression in cells transfected with progesterone receptor-B

• Comparative analysis:

  • Always include appropriate normal tissue controls

  • Consider gradient expression patterns rather than binary positive/negative classification

How can KCNH1 antibodies be integrated with genetic analysis techniques?

Modern research often combines antibody-based protein detection with genetic analysis for comprehensive understanding:

• Paired antibody staining and RNA expression:

  • Correlate KCNH1 protein levels (antibody detection) with mRNA expression (qPCR)

  • Use dual RNA-protein detection methods for single-cell analysis

  • Real-time PCR protocols for KCNH1 have been validated using primers: cct gga ggt gat cca aga tg (forward), cca aac acg tct cct ttt cc (reverse)

• Variant impact assessment:

  • Use whole-exome sequencing to identify KCNH1 variants

  • Follow with antibody-based assays to assess variant effects on expression

  • Integrate protein modeling with antibody localization studies to understand structural impacts

• Knockout/knockdown validation:

  • Confirm antibody specificity in CRISPR knockout models

  • Use siRNA knockdown followed by antibody detection to confirm target reduction

  • Employ inducible expression systems for temporal control of KCNH1 expression

What are the considerations for co-immunoprecipitation experiments with KCNH1?

Co-immunoprecipitation (Co-IP) is valuable for studying KCNH1 interactions but requires optimization:

• Antibody selection:

  • Choose antibodies raised against epitopes not involved in protein-protein interactions

  • Validate antibodies specifically for immunoprecipitation efficiency

  • Consider using epitope-tagged KCNH1 constructs as alternatives

• Sample preparation:

  • Use mild detergents (0.5-1% NP-40 or Triton X-100) to preserve protein-protein interactions

  • Include phosphatase inhibitors to maintain phosphorylation states

  • Optimize salt concentration (typically 150mM NaCl) to balance specificity and efficiency

• Controls:

  • Include IgG control immunoprecipitations

  • Validate specificity using KCNH1-depleted samples

  • Consider reverse Co-IP to confirm interactions

• Analysis:

  • Use gradient gels for detecting high molecular weight complexes

  • Apply sensitive detection methods (e.g., fluorescent secondary antibodies)

  • Consider mass spectrometry for unbiased interaction partner identification

How are KCNH1 antibodies being used in therapeutic development?

KCNH1 represents an emerging therapeutic target, particularly for neurodevelopmental disorders and cancer:

• Therapeutic antibody development:

  • Anti-KCNH1 antibodies can be used to screen for channel-blocking compounds

  • Extracellular epitope-targeting antibodies may directly modulate channel function

  • Antibody-drug conjugates targeting KCNH1 in cancer cells show promise

• CAR-T cell therapy:

  • Anti-KCNH1 chimeric antigen receptors are being developed for targeting KCNH1-expressing cancers

  • Vectors expressing scFv of anti-KCNH1 antibody linked to CD28 and CD3ζ signaling domains show potential for brainstem glioma treatment

• Drug repurposing strategies:

  • Antibodies validate KCNH1 expression before testing channel modulators

  • The KCNH1 Cure Roadmap focuses on drug repurposing and antisense oligonucleotide (ASO) approaches

What are the future directions for KCNH1 antibody development and applications?

The field of KCNH1 research is rapidly evolving with several exciting directions:

• Variant-specific antibodies:

  • Development of antibodies that specifically recognize common pathogenic variants

  • Application in personalized medicine approaches

  • Use in monitoring variant-specific therapeutics

• Multiplexed detection systems:

  • Integration with other ion channel markers for comprehensive profiling

  • Development of antibody panels for neurological disorder classification

  • Combination with electrophysiological recording techniques

• Live-cell imaging applications:

  • Non-permeabilizing antibodies against extracellular domains for live cell studies

  • Development of antibody-based biosensors for real-time monitoring

  • Antibody fragments for improved tissue penetration

• Therapeutic approaches:

  • Ongoing research indicates KCNH1 variants associated with neurodevelopmental disorders exhibit gain-of-function properties

  • This mechanistic insight drives targeted therapeutic development

  • Precision medicine approaches aim to address specific variants through ASO technology

What are common challenges in KCNH1 antibody applications and how can they be addressed?

Researchers frequently encounter several issues when working with KCNH1 antibodies:

• High background in immunostaining:

  • Increase blocking time and concentration (use 5-10% serum)

  • Optimize antibody concentration with titration experiments

  • Include additional washing steps with 0.1% Tween-20

  • Use secondary antibodies pre-adsorbed against tissue species

• Multiple bands in Western blot:

  • KCNH1 can be post-translationally modified, creating multiple bands

  • Use fresh samples with complete protease inhibitor cocktails

  • Include phosphatase inhibitors to preserve phosphorylation states

  • Validate with positive controls (HEK293T cells expressing KCNH1)

• Inconsistent immunoprecipitation results:

  • Optimize lysis conditions with different detergent combinations

  • Extend antibody incubation time (overnight at 4°C)

  • Cross-link antibody to beads to prevent antibody contamination in eluted samples

  • Use specific elution conditions that preserve epitope recognition

• Weak signal in difficult tissues:

  • Extend antigen retrieval time for fixed tissues

  • Try alternative fixation methods (paraformaldehyde vs. methanol)

  • Employ signal amplification systems (tyramide signal amplification)

  • Use alternative detection systems (enhance chemiluminescence substrates)

How can researchers validate KCNH1 antibody specificity?

Thorough validation is critical for ensuring antibody specificity:

• Multiple antibody approach:

  • Compare staining patterns using antibodies targeting different KCNH1 epitopes

  • Confirm consistent results with monoclonal and polyclonal antibodies

  • Use orthogonal detection methods (protein vs. mRNA)

• Genetic validation:

  • Test antibodies on KCNH1 knockout or knockdown samples

  • Compare wild-type and variant-expressing cells

  • Use siRNA-mediated knockdown for specificity confirmation

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide to block specific binding

  • Include graduated peptide concentrations for dose-dependent blocking

  • Use irrelevant peptides as negative controls

• Cross-reactivity assessment:

  • Test on samples expressing related channels (KCNH2, KCNH5)

  • Examine species cross-reactivity for evolutionary studies

  • Compare results with predicted molecular weight and expression patterns